Cochrane · systematic review · CD000458
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
El‐Sayeh, HG, Rathbone, J, Soares‐Weiser, K, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 11 · 45.8%Very low 11 · 45.8%Low 2 · 8.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement NORADRENERGIC DRUGS vs PLACEBO | RR 0.33 [0.14, 0.8] | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: deterioration NORADRENERGIC DRUGS vs PLACEBO | RR 0.33 [0.02, 7.32] | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events ‐ not reported NORADRENERGIC DRUGS vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state ‐ not reported NORADRENERGIC DRUGS vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
Acceptability of treatment: Leaving the study early NORADRENERGIC DRUGS vs PLACEBO | RR 5.28 [0.27, 102.58] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
No improvement in quality of life NORADRENERGIC DRUGS vs PLACEBO | RR 0.87 [0.68, 1.12] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic‐induced tardive dyskinesia
Population: patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | RR 0.6 [0.19, 1.86] | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events ‐ not reported NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state ‐ not reported NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Acceptability of treatment: Leaving the study early NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement DOPAMINERGIC DRUGS vs PLACEBO | RR 0.52 [0.29, 0.96] | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration DOPAMINERGIC DRUGS vs PLACEBO | RR 1.18 [0.35, 3.99] | 2 studies · 37 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events ‐ not reported DOPAMINERGIC DRUGS vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
General mental state: Deterioration DOPAMINERGIC DRUGS vs PLACEBO | RR 2.2 [0.22, 22.45] | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision |
Acceptability of treatment: Leaving the study early DOPAMINERGIC DRUGS vs PLACEBO | RR 1.29 [0.65, 2.54] | 6 studies · 163 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported DOPAMINERGIC DRUGS vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic‐induced tardive dyskinesia
Population: patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement DOPAMINERGIC DRUGS vs OTHER DRUGS | RR 0.93 [0.45, 1.95] | 1 study · 13 participants | Very low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration DOPAMINERGIC DRUGS vs OTHER DRUGS | RR 1.17 [0.09, 14.92] | 1 study · 13 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events ‐ not reported DOPAMINERGIC DRUGS vs OTHER DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state ‐ not reported DOPAMINERGIC DRUGS vs OTHER DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Acceptability of treatment: Leaving the study early DOPAMINERGIC DRUGS vs OTHER DRUGS | RR 0.23 [0.01, 4] | 1 study · 13 participants | Very low Downgraded: risk of bias, imprecision |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported DOPAMINERGIC DRUGS vs OTHER DRUGS | no estimate extracted | 0 studies · 0 participants | Ungraded |